Oral Supplementation with Sucrosomial Ferric Pyrophosphate Plus L-Ascorbic Acid to Ameliorate the Martial Status: A Randomized Controlled Trial.
Study Goal
The researchers aimed to determine whether a 30-day oral therapy of sucrosomial ferric pyrophosphate plus L-ascorbic acid could optimize preoperative martial status and reduce complications in patients undergoing elective hip/knee arthroplasty.
Results Summary
The study found that the iron formula was well-tolerated (2.7% adverse events) and effective in older patients (≥65 years), averting hemoglobin loss (-2.8% in controls vs. +0.7% in the intervention group). Efficacy was limited to older patients, with no significant effect observed in younger individuals.
Population
Patients undergoing elective hip/knee arthroplasty, with notable efficacy in those ≥65 years old.
Effective Dosage
30-day oral therapy of sucrosomial ferric pyrophosphate plus L-ascorbic acid (specific dosage not provided).
Duration
30 days
Interactions
None mentioned
| Intervention | Direction | Endpoint | Population | Dosage | Impact | Claim # |
|---|---|---|---|---|---|---|
Oral supplements | increase | preoperative martial status | - | - | can optimize | #1 |
a 30-day oral therapy of sucrosomial ferric pyrophosphate plus L-ascorbic acid | neutral | tolerability | treated patients | 2.7% | The tolerability was | #2 |
iron formula | no change | Hb loss | older patients (≥ 65 years old) | - | uncharacterized Hb loss was averted upon treatment | #3 |
- | decrease | circulating hemoglobin | Older patients with no support | -2.8 ± 5.1% | lost | #4 |
iron formula | increase | circulating hemoglobin | the intervention group | +0.7 ± 4.6% | gained | #5 |
Altered martial indices before orthopedic surgery are associated with higher rates of complications and greatly affect the patient's functional ability. Oral supplements can optimize the preoperative martial status, with clinical efficacy and the patient's tolerability being highly dependent on the pharmaceutical formula. Patients undergoing elective hip/knee arthroplasty were randomized to be supplemented with a 30-day oral therapy of sucrosomial ferric pyrophosphate plus L-ascorbic acid. The tolerability was 2.7% among treated patients. Adjustments for confounding factors, such as iron absorption influencers, showed a relevant response limited to older patients (≥ 65 years old), whose uncharacterized Hb loss was averted upon treatment with iron formula. Older patients with no support lost -2.8 ± 5.1%, while the intervention group gained +0.7 ± 4.6% of circulating hemoglobin from baseline (